Amphastar Pharmaceuticals (AMPH) Deferred Taxes (2013 - 2021)

Amphastar Pharmaceuticals' Deferred Taxes history runs 5 years deep, the most recent figure standing at $2.8 million for Q4 2021.

• On a quarterly basis, Deferred Taxes fell 26.79% year-over-year to $2.8 million in Q4 2021; TTM through Dec 2021 was $4.6 million, a 2728.4% increase from a year earlier, with the FY2025 full-year figure at -$28.7 million, down 260.36% from the prior year.
• Deferred Taxes retreated to $2.8 million in Q4 2021 per AMPH's latest filing, from $3.8 million in the prior quarter.
• Across five years, Deferred Taxes topped out at $5.3 million in Q4 2019 and bottomed at -$2.0 million in Q3 2020.
• The 3-year median for Deferred Taxes is $2.8 million (2021), against an average of $1.7 million.
• Across the five-year window, Deferred Taxes retreated 28.71% in 2020 and retreated 26.79% in 2021, its largest moves.
• Year by year, Deferred Taxes stood at $5.3 million in 2019, then slipped by 28.71% to $3.8 million in 2020, then decreased by 26.79% to $2.8 million in 2021.
• Per Business Quant, the three latest AMPH Deferred Taxes figures stand at $2.8 million (Q4 2021), $3.8 million (Q4 2020), and -$2.0 million (Q3 2020).